CoChat

Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation and Symptomatic Heart Failure: A Subgroup Analysis of the RE-LY Trial

Ferreira, Jorge, Ezekowitz, Michael D., Connolly, Stuart J., Brueckmann, Martina, Fraessdorf, Mandy, Reilly, Paul A., Yusuf, Salim, Wallentin, Lars · 2013 · European Journal of Heart Failure
Cited by 98

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aims: We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure (HF) in the RE-LY trial. Methods and results: RE-LY compared two fixed and blinded doses of dabigatran (110 and 150 mg twice daily) with open-label warfarin in 18 113 patients with AF at increased risk for stroke. Among 4904 patients with HF, annual rates of stroke or systemic embolism (SE) were 1.92% for patients on warfarin compared with 1.90% for dabigatran 110 mg [hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.69–1.42] and 1.44% for dabigatran 150 mg (HR 0.75, 95% CI 0.51–1.10). Annual rates of major bleeding were 3.90% for the group on warfarin, compared with 3.26% for dabigatran 110 mg (HR 0.83, 95% CI 0.64–1.09) and 3.10% for dabigatran 150 mg (HR 0.79, 95% CI 0.60–1.03). Rates of intracranial bleeding were significantly lower for both dabigatran dosages compared with warfarin in patients with HF (dabigatran 110 mg vs. warfarin, HR 0.34, 95% CI 0.14–0.80; dabigatran 150 mg vs. warfarin, HR 0.39, 95% CI 0.17–0.89). The relative effects of dabigatran vs. warfarin on the occurrence of stroke or SE and major bleeding were consistent among those with and without HF and those with low (≤40%) or preserved (>40%) LVEF (P interaction not significant). Conclusions: The overall benefits of dabigatran for stroke/SE prevention, and major and intracranial bleeding, relative to warfarin in the RE-LY trial were consistent in patients with and without HF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hft111

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 24

  1. Cleland, 2001, The heart failure epidemic: exactly how big is it?, Eur Heart J, 22, 623, 10.1053/euhj.2000.2493 · DOI · Paper page
  2. Nieuwlaat, 2009, Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation, J Am Coll Cardiol, 53, 1690, 10.1016/j.jacc.2009.01.055 · DOI
  3. Maisel, 2003, Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy, Am J Cardiol, 91, 2D, 10.1016/S0002-9149(02)03373-8 · DOI · Paper page
  4. Dries, 1998, Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction, J Am Coll Cardiol, 32, 695, 10.1016/S0735-1097(98)00297-6 · DOI · Paper page
  5. 2007, Stroke in AF working group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review, Neurology, 69, 546, 10.1212/01.wnl.0000267275.68538.8d · DOI · Paper page
  6. Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278 · DOI · Paper page
  7. Camm, 2012, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation, Eur Heart J, 33, 2719
  8. Witt, 2010, Warped Consortium. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users, J Thromb Haemost, 8, 744, 10.1111/j.1538-7836.2010.03756.x · DOI
  9. Lip, 2011, Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score, J Am Coll Cardiol, 57, 173, 10.1016/j.jacc.2010.09.024 · DOI · Paper page
  10. DiMarco, 2005, AFFIRM Investigators. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study, Am Heart J, 149, 650, 10.1016/j.ahj.2004.11.015 · DOI · Paper page
  11. Cleland, 2007, Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials, Eur J Heart Fail, 9, 730, 10.1016/j.ejheart.2007.01.013 · DOI
  12. Ezekowitz, 2009, Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran, Am Heart J, 157, 805, 10.1016/j.ahj.2009.02.005 · DOI · Paper page
  13. Wallentin, 2010, on behalf of the RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4 · DOI · Paper page
  14. Oldgren, 2012, on behalf of the RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial, Ann Intern Med, 155, 660, 10.7326/0003-4819-155-10-201111150-00004 · DOI · Paper page
  15. Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 · DOI · Paper page
  16. Mulder, 2012, Stroke aetiology in heart failure: towards patient-tailored prevention of stroke, Eur J Heart Fail, 14, 230, 10.1093/eurjhf/hfs018 · doi:10.1093/eurjhf/hfs018
  17. Ogilvie, 2010, Underuse of oral anticoagulants in atrial fibrillation: a systematic review, Am J Med, 123, 638, 10.1016/j.amjmed.2009.11.025 · DOI · Paper page
  18. Ahmad, 2012, New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation, Expert Rev Cardiovasc Ther, 10, 1471, 10.1586/erc.12.148 · DOI · Paper page
  19. Choudry, 2006, Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis, BMJ, 332, 141, 10.1136/bmj.38698.709572.55 · DOI · Paper page
  20. Ferrari, 2007, for the ALPHA Study Group. Atrial fibrillation in heart failure patients: prevalence in daily clinical practice and effect on the severity of symptoms. Data from the ALPHA study registry, Eur J Heart Fail, 9, 502, 10.1016/j.ejheart.2006.10.021 · DOI
  21. Bourlag, 2011, Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment, Eur Heart J, 32, 670, 10.1093/eurheartj/ehq426 · DOI · Paper page
  22. Banerjee, 2012, Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project, Eur J Heart Fail, 14, 295, 10.1093/eurjhf/hfs005 · DOI · Paper page
  23. Huisman, 2012, Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice, Thromb Haemost, 107, 838, 10.1160/TH11-10-0718 · DOI · Paper page
  24. Yusuf, 1993, Design, results and interpretation of randomized, controlled trials in congestive heart failure and left ventricular dysfunction, Circulation, 87(Suppl. VII), 115

Cited by

See all 98

Metadata

Authors
Ferreira, J., Ezekowitz, M. D., Connolly, S. J., Brueckmann, M., Fraessdorf, M., Reilly, P. A., Yusuf, S., & Wallentin, L.
Venue
European Journal of Heart Failure
Published
2013-09-01
Volume
15
Issue
9
Pages
1053-1061
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2007272937
Cited by
98
References
8
FWCI
8.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation and Symptomatic Heart Failure: A Subgroup Analysis of the RE-LY Trial. https://app.cochat.ai/papers/10.1093/eurjhf/hft111
The paper
Ferreira, J., Ezekowitz, M. D., Connolly, S. J., Brueckmann, M., Fraessdorf, M., Reilly, P. A., Yusuf, S., & Wallentin, L. (2013). Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation and Symptomatic Heart Failure: A Subgroup Analysis of the RE-LY Trial. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hft111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.